Galderma sues Lupin over Oracea generic
07-12-2021
Nestlé Skin Health has face injection infringement claims thrown out
17-12-2019
JHVEphoto / Shutterstock.com
The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Galderma, Nestlé Skin Health, Teva, generics, rosacea, ANDA, Soolantra, patent infringement, patentability
